Welcome to our dedicated page for Polomar Health SEC filings (Ticker: PMHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Polomar Health Services, Inc. (PMHS) SEC filings provide detailed insight into the company’s structure, pharmacy operations and corporate transactions. As a Nevada corporation and smaller reporting company, Polomar submits registration statements, current reports and periodic reports under the Securities Act of 1933 and the Securities Exchange Act of 1934.
The company’s Form S-1 and S-1/A registration statements describe its business as operating Polomar Specialty Pharmacy, LLC, a State of Florida licensed retail compounding pharmacy with a Special Sterile Compounding Pharmacy permit. These filings explain that the compounding facility works under Section 503A of the Federal Food, Drug and Cosmetic Act, and they outline the terms of registered common stock, selling stockholder resale offerings and the company’s status as a non-accelerated filer and smaller reporting company.
Current reports on Form 8-K document material events. One 8-K filed in October 2025 reports a First Amendment to an Agreement and Plan of Merger and Reorganization with Altanine Inc., changing the exchange ratio for common and preferred stock in the contemplated merger. Another 8-K filed in December 2025 describes a Second Amendment to an Amended and Restated Product Fulfillment and Distribution Agreement with ForHumanity, Inc. and Island Group 40, LLC, including revised exclusivity periods, termination rights linked to sales performance and an updated schedule of guaranteed payments.
The Form 12b-25 (NT 10-Q) filing for the quarter ended September 30, 2025, explains a delay in filing the related Form 10-Q and discusses anticipated changes in results of operations following the merger with Polomar Specialty Pharmacy. It also notes that the merger is treated as a reverse recapitalization and that the registrant ceased commercializing its pre-merger business. Through Stock Titan, users can access these PMHS filings as they are made available on EDGAR and review AI-assisted summaries that highlight key terms in S-1, 8-K, 10-Q and related documents, as well as disclosures about merger activity, product fulfillment agreements and the regulatory framework for the company’s compounding pharmacy.
Polomar Health Services, Inc. filed a late notice for its Q3 2025 Form 10‑Q, citing unexpected delays in completing financial statements and stating it expects to file within five calendar days.
The company highlighted significant operational changes following its September 30, 2024 reverse recapitalization with Polomar Specialty Pharmacy and a shift from retail to wholesale. For the nine months ended September 30, 2025, revenue was approximately $16,174 versus $37,954 a year earlier, while operating expenses were approximately $1,618,886 versus $632,217. The company reported a net loss of approximately $1,712,194 compared with $622,544 in the prior period, reflecting higher legal, accounting, consulting, interest, and payroll costs.
Polomar Health Services, Inc. announced a First Amendment to its Agreement and Plan of Merger and Reorganization with Altanine Inc., updating the exchange terms for the planned combination. The amendment defines the “Exchange Ratio” as one share of Parent Common Stock for each share of Company Common Stock and five shares of Parent Preferred Stock for each share of Company Preferred Stock, subject to adjustment.
The amendment, dated October 8, 2025, applies to the merger among Polomar Health, its wholly owned subsidiary Polomar Merger Sub, Inc., and Altanine Inc. The company attached the full amendment as Exhibit 2.1 and incorporated it by reference.
Polomar Health Services (PMHS) insider buying disclosed on Form 4. Terrence M. Tierney, President and Director, reported three open-market purchases: 125,000 shares on 06/27/2025, 8,333 shares on 07/15/2025 and 7,695 shares on 08/15/2025, bringing his beneficial ownership to 141,028 shares. Reported aggregate cash amounts are shown for each lot on the form. The Form 4 is signed by the reporting person.
Polomar Health Services, Inc. filed an S-1 describing a recent recapitalization, related-party financings, and material liquidity constraints. The company sold 90,437,591 common shares (about 83% of issued and outstanding) and 500,000 Series A preferred shares to CWR 1, LLC for $350,000. The former CEO and chairman resigned. The filing discloses multiple promissory notes and related-party advances including a Reprise Note with outstanding principal of $716,402.67 and accrued interest of $29,508.91 as of December 31, 2024 (amended and larger balances reported through June 30, 2025), a $150,000 CWR Note II with initial 12% APR and milestone draws, and other notes exchanged for preferred stock.
The company reported no cash equivalents, net loss of $1,341,333 for 2024, accumulated deficit of $2,911,163 as of December 31, 2024 (increased to $3,973,581 as of June 30, 2025), and explicit substantial doubt about its ability to continue as a going concern within one year.